Page last updated: 2024-10-21

urea and Disease Exacerbation

urea has been researched along with Disease Exacerbation in 75 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Research Excerpts

ExcerptRelevanceReference
"The urine-to-plasma urea ratio, which is calculated from routine laboratory measurements, predicts disease progression in ADPKD in addition to other risk markers."8.02Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. ( Boertien, WE; Casteleijn, NF; Gansevoort, RT; Heida, JE; Meijer, E; Messchendorp, AL; Zittema, D, 2021)
" In the present study, blood triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) breakdown pathway was evaluated in relation to uric acid concentration and xanthine dehydrogenase/xanthine oxidase (XDH/XO) in patients with essential hypertension, patients with chronic renal diseases on dialysis, and control individuals."7.80Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. ( Boban, M; Bobana, MD; Cvetkovic, T; Deljanin-Ilic, M; Djindjic, B; Ilic, S; Jevtovic-Stoimenov, T; Kocic, G; Pavlovic, R; Radenkovic, S; Sokolovic, D; Stojanovic, D, 2014)
"The urine-to-plasma urea ratio, which is calculated from routine laboratory measurements, predicts disease progression in ADPKD in addition to other risk markers."4.02Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression. ( Boertien, WE; Casteleijn, NF; Gansevoort, RT; Heida, JE; Meijer, E; Messchendorp, AL; Zittema, D, 2021)
"In rats of group 1, serum levels of creatinine and urea and microalbuminuria were increased, while reduced creatinine clearance (p<0."3.83Characterization of an experimental model of progressive renal disease in rats. ( Baracho, NC; Kangussu, LM; Pereira, RM; Prestes, TR; Rocha, NP; Silva, AC; Silveira, KD, 2016)
" In the present study, blood triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) breakdown pathway was evaluated in relation to uric acid concentration and xanthine dehydrogenase/xanthine oxidase (XDH/XO) in patients with essential hypertension, patients with chronic renal diseases on dialysis, and control individuals."3.80Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. ( Boban, M; Bobana, MD; Cvetkovic, T; Deljanin-Ilic, M; Djindjic, B; Ilic, S; Jevtovic-Stoimenov, T; Kocic, G; Pavlovic, R; Radenkovic, S; Sokolovic, D; Stojanovic, D, 2014)
" Between 6 and 12 months of age, eSS male rats had higher fructosamine values and glucose intolerance as well as increasing proteinuria and uremia."3.70Onset and evolution of nephropathy in rats with spontaneous diabetes mellitus. ( Arriaga, S; D'Ottavio, AE; Daniele, SM; Hisano, N; Martínez, SM; Montenegro, SM; Morisoli, L; Picena, JC; Tarrés, MC, 2000)
"Of the 85 patients with advanced gastrointestinal stromal tumor having received at least three prior anticancer therapies randomized to ripretinib 150 mg once daily (QD) in the phase III INVICTUS study, 43 underwent ripretinib intrapatient dose escalation (IPDE) to 150 mg b."3.01Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. ( Attia, S; Bauer, S; Blay, JY; Chi, P; D'Amato, G; Gelderblom, H; George, S; Heinrich, MC; Jones, RL; Meade, J; Reichardt, P; Reichert, V; Ruiz-Soto, R; Schöffski, P; Serrano, C; Sherman, ML; Shi, K; Somaiah, N; von Mehren, M; Zalcberg, JR, 2021)
" The oral bioavailability of AT9283 was assessed in a cohort of seven patients."2.77A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. ( Arkenau, HT; Calvert, H; Judson, I; Lewis, S; Lock, V; Lyons, J; Molife, LR; Olmos, D; Plummer, R; Squires, M; Yap, TA; Yule, M, 2012)
"Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year."2.75Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010)
"Thirty hypertensive diabetic nephropathy patients with moderate hypertension were studied."2.70Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy. ( Arije, A; Finomo, FO; Kadiri, S; Olatosin, AO; Salako, BL, 2002)
"In both groups of patients with chronic renal failure, i."2.70Circadian serum melatonin profiles in patients suffering from chronic renal failure. ( Chrzanowski, W; Karasek, M; Swietoslawski, J; Szuflet, A; Zylinska, K, 2002)
"Hyperkalemia is associated with kidney function decline in patients with non-dialysis dependent chronic kidney disease, but this relationship is unclear for residual kidney function (RKF) among hemodialysis (HD) patients."1.72Association of serum potassium with decline in residual kidney function in incident hemodialysis patients. ( Arif, Y; Edward, A; Hanna, RM; Hsiung, JT; Kalantar-Zadeh, K; Kovesdy, CP; Lau, WL; Lee, Y; Obi, Y; Streja, E; Wenziger, C, 2022)
" Treatment-emergent adverse events (TEAEs) were summarised by dosing periods and compared descriptively."1.62Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. ( Chi, P; Ganjoo, K; Gelderblom, H; George, S; Gordon, MS; Heinrich, MC; Janku, F; Jennings, J; Jones, RL; Meade, J; Razak, AA; Ruiz-Soto, R; Shi, K; Somaiah, N; Su, Y; Trent, J; von Mehren, M, 2021)
"(1) Background: Successful treatment of acute kidney injury (AKI)-induced chronic kidney disease (CKD) is unresolved."1.56Post-Ischemic Renal Fibrosis Progression Is Halted by Delayed Contralateral Nephrectomy: The Involvement of Macrophage Activation. ( Bukosza, EN; Fintha, A; Hamar, P; Kaucsár, T; Krenács, T; Róka, B; Szénási, G; Tod, P, 2020)
"Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from steatosis, through non-alcoholic steatohepatitis (NASH) to cirrhosis."1.48Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. ( Andreola, F; De Chiara, F; Jalan, R; Mookerjee, RP; Rombouts, K; Thomsen, KL; Vilstrup, H, 2018)
"ADAMTS13 retards progression of diabetic nephropathy, most likely by inhibiting VWF-dependent intrarenal thrombosis."1.46ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice. ( Chauhan, AK; Chorawala, MR; Dhanesha, N; Doddapattar, P; Kokame, K; Lentz, SR; Nayak, MK; Staber, JM, 2017)
" Histopathological and biochemical alterations of post-UN dosing in comparison to control were evaluated."1.43Biochemical and histopathological responses of the Swiss albino mice treated with uranyl nitrate and its recovery. ( Arun, AB; Dinesh, U; Rekha, PD; Sangeetha Vijayan, P, 2016)
"Nonalcoholic steatohepatitis (NASH) is increasing in prevalence, yet its consequences for liver function are unknown."1.40Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. ( Clouston, A; George, J; Glavind, E; Grønbæk, H; Hebbard, L; Jessen, N; Thomsen, KL; Vilstrup, H, 2014)
"Also, in kidneys of ADPKD patients collapsed cysts were observed, in addition to massive fibrosis and immune infiltrates."1.39Cyst expansion and regression in a mouse model of polycystic kidney disease. ( Breuning, MH; de Heer, E; Happé, H; Leonhard, WN; Peters, DJ; Salvatori, DC; van der Wal, AM, 2013)
"Sepsis is the most common trigger for acute kidney injury (AKI) in critically ill patients."1.38A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. ( Bagshaw, SM; Bellomo, R; Bennett, M; Devarajan, P; Haase, M; Haase-Fielitz, A, 2012)
"Urea appears to be a stronger marker of an adverse prognosis than creatinine-based measures of renal function."1.38Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. ( Antony, R; Carubelli, V; Castiello, T; Cleland, JG; Pellicori, P; Yassin, A, 2012)
"University of California-Davis-type 2 diabetes mellitus (UCD-T2DM) rats with nonfasting blood glucose levels in the range of 150-200 mg/dl were treated with the sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) for 6 wk."1.38Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. ( Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V, 2012)
"Hospitalization for exacerbation of COPD is associated with a high risk of mortality."1.37Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. ( Chang, CL; Hancox, RJ; Karalus, NC; McLachlan, JD; Mills, GD; Sullivan, GD, 2011)
"Diabetic nephropathy is the common cause of leading to end stage of renal disease (ESRD)."1.37Satureja khozestanica essential oil ameliorates progression of diabetic nephropathy in uninephrectomized diabetic rats. ( Ahmadvand, H; Delfan, B; Khalatbari, AR; Tamjidipoor, A; Tavafi, M, 2011)
"In conclusion, IFN-beta treatment of lupus nephritis in MRL-Fas(lpr) mice is remarkably beneficial and suggests that IFN-beta may be an appealing therapeutic candidate for subtypes of human lupus."1.33Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. ( Brenner, W; Galle, PR; Hansen, T; Kelley, VR; Menke, J; Paul, K; Relle, M; Schwarting, A; Tschirner, S, 2005)
"An exact description of the course of chronic renal failure in this strain, however, is still missing."1.29Progression of chronic renal failure in a rat strain with autosomal dominant polycystic kidney disease. ( Gretz, N, 1994)
"In horses with hepatic necrosis, lipidosis, neoplasia and cirrhosis, progression of the disease was studied by serial measurements of total serum bile acid concentrations and of plasma glutamate dehydrogenase (GD) and gamma glutamyl transferase (gamma GT) and by liver biopsy."1.29Clinical and pathological studies in horses with hepatic disease. ( West, HJ, 1996)

Research

Studies (75)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (8.00)18.2507
2000's18 (24.00)29.6817
2010's40 (53.33)24.3611
2020's11 (14.67)2.80

Authors

AuthorsStudies
Bakht, MK1
Hayward, JJ1
Shahbazi-Raz, F1
Skubal, M1
Tamura, R1
Stringer, KF1
Meister, D1
Venkadakrishnan, VB1
Xue, H1
Pillon, A1
Stover, M1
Tronchin, A1
Fifield, BA1
Mader, L1
Ku, SY1
Cheon, GJ2
Kang, KW2
Wang, Y3
Dong, X2
Beltran, H1
Grimm, J1
Porter, LA1
Trant, JF1
Arif, Y1
Wenziger, C1
Hsiung, JT1
Edward, A1
Lau, WL1
Hanna, RM1
Lee, Y2
Obi, Y2
Kovesdy, CP2
Kalantar-Zadeh, K2
Streja, E2
Okuda, Y1
Sy, J1
Kim, SR1
Rhee, CM1
Mahdavi, S1
Yared, K1
Wu, G2
Omar, B1
Savundra, D1
Nagai, G1
Hockmann, E1
Svendrovski, A1
Bellasi, A1
Tam, P1
Sikaneta, T1
Fernández Lucas, M1
Ruíz-Roso, G2
Merino, JL1
Sánchez, R2
Bouarich, H1
Herrero, JA1
Muriel, A1
Zamora, J1
Collado, A1
Tod, P1
Bukosza, EN1
Róka, B1
Kaucsár, T1
Fintha, A1
Krenács, T1
Szénási, G1
Hamar, P1
Zukotynski, KA1
Jadvar, H1
Potvin, K1
Cho, SY1
Kim, CK1
Winquist, E1
Sivangala Thandi, R1
Radhakrishnan, RK1
Tripathi, D1
Paidipally, P1
Azad, AK1
Schlesinger, LS1
Samten, B1
Mulik, S1
Vankayalapati, R1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y4
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L2
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z3
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X6
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W2
Zhang, Y4
Wu, X2
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y2
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W2
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q3
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Ethier, I1
Cho, Y1
Hawley, C1
Pascoe, EM1
Viecelli, AK1
Campbell, SB1
van Eps, C1
Isbel, NM1
Cooper, BA1
Harris, DC1
Pollock, CA1
Wong, MG1
Johnson, DW1
Heida, JE1
Gansevoort, RT2
Messchendorp, AL1
Meijer, E2
Casteleijn, NF1
Boertien, WE1
Zittema, D1
Zalcberg, JR1
Heinrich, MC2
George, S2
Bauer, S1
Schöffski, P1
Serrano, C1
Gelderblom, H2
Jones, RL2
Attia, S1
D'Amato, G1
Chi, P2
Reichardt, P1
Somaiah, N2
Meade, J2
Reichert, V1
Shi, K2
Sherman, ML1
Ruiz-Soto, R2
von Mehren, M2
Blay, JY1
Ganjoo, K1
Trent, J1
Razak, AA1
Gordon, MS1
Jennings, J1
Su, Y1
Janku, F1
Dhanesha, N1
Doddapattar, P1
Chorawala, MR1
Nayak, MK1
Kokame, K1
Staber, JM1
Lentz, SR1
Chauhan, AK1
Long, Y1
Sanchez-Espiridion, B1
Lin, M1
White, L1
Mishra, L1
Raju, GS1
Kopetz, S1
Eng, C1
Hildebrandt, MAT1
Chang, DW1
Ye, Y1
Liang, D1
Di Iorio, BR1
Marzocco, S1
Nardone, L1
Sirico, M1
De Simone, E1
Di Natale, G1
Di Micco, L1
Pojskić, L1
Hasić, S1
Tahto, E1
Arnautović-Torlak, V1
Pojskić, B1
Thomsen, KL2
De Chiara, F1
Rombouts, K1
Vilstrup, H2
Andreola, F1
Mookerjee, RP1
Jalan, R1
Tao, S2
Cheng, Y1
Liu, J1
Ma, L1
Fu, P1
Otero Alonso, P1
Pérez Fontán, M1
López Iglesias, A1
García Falcón, T1
Rodríguez-Carmona, A1
Happé, H1
van der Wal, AM1
Salvatori, DC1
Leonhard, WN1
Breuning, MH1
de Heer, E1
Peters, DJ1
Guan, M1
Xie, L1
Diao, C1
Wang, N1
Gao, H1
Elmarakby, AA1
Faulkner, J1
Pye, C1
Rouch, K1
Alhashim, A1
Maddipati, KR1
Baban, B1
Poli, G1
Corda, E1
Martino, PA1
Dall'ara, P1
Bareggi, SR1
Bondiolotti, G1
Iulini, B1
Mazza, M1
Casalone, C1
Hwang, SH1
Hammock, BD2
Inceoglu, B1
Kemter, E1
Prueckl, P1
Sklenak, S1
Rathkolb, B1
Habermann, FA1
Hans, W1
Gailus-Durner, V1
Fuchs, H1
Hrabě de Angelis, M1
Wolf, E1
Aigner, B1
Wanke, R1
Dammermann, W1
Schipper, P1
Ullrich, S1
Fraedrich, K1
Schulze Zur Wiesch, J1
Fründt, T1
Tiegs, G1
Lohse, A1
Lüth, S1
Teruel-Briones, JL1
Fernández-Lucas, M1
Rivera-Gorrin, M1
Díaz-Domínguez, M1
Rodríguez-Mendiola, N1
Quereda-Rodríguez-Navarro, C1
Foran, J1
Ravandi, F1
Wierda, W1
Garcia-Manero, G1
Verstovsek, S1
Kadia, T1
Burger, J1
Yule, M2
Langford, G1
Lyons, J2
Ayrton, J1
Lock, V2
Borthakur, G1
Cortes, J1
Kantarjian, H1
Sliwińska-Mossoń, M1
Topoła, M1
Milnerowicz, S1
Milnerowicz, H1
Boban, M1
Kocic, G1
Radenkovic, S1
Pavlovic, R1
Cvetkovic, T1
Deljanin-Ilic, M1
Ilic, S1
Bobana, MD1
Djindjic, B1
Stojanovic, D1
Sokolovic, D1
Jevtovic-Stoimenov, T1
Grønbæk, H1
Glavind, E1
Hebbard, L1
Jessen, N1
Clouston, A1
George, J1
Zhang, YF1
He, F1
Ding, HH1
Dai, W1
Luan, H1
Lv, YM1
Zeng, HB1
Chiavaroli, L1
Mirrahimi, A1
Sievenpiper, JL1
Jenkins, DJ1
Darling, PB1
van Gastel, MD1
Scheven, LE1
Struck, J1
Bakker, SJ1
Chen, CM2
Lin, YS1
Wu, YR2
Chen, P1
Tsai, FJ1
Yang, CL1
Tsao, YT1
Chang, W1
Hsieh, IS1
Chern, Y2
Soong, BW2
Bojic, S1
Kotur-Stevuljevic, J1
Kalezic, N1
Stevanovic, P1
Jelic-Ivanovic, Z1
Bilanovic, D1
Memon, L1
Damnjanovic, M1
Kalaba, Z1
Simic-Ogrizovic, S1
Sangeetha Vijayan, P1
Rekha, PD1
Dinesh, U1
Arun, AB1
Gil, A1
Brod, V1
Awad, H1
Heyman, SN1
Abassi, Z1
Frajewicki, V1
Baracho, NC1
Kangussu, LM1
Prestes, TR1
Silveira, KD1
Pereira, RM1
Rocha, NP1
Silva, AC1
Afshar-Oromieh, A1
Haberkorn, U1
Zechmann, C1
Armor, T1
Mier, W1
Spohn, F1
Debus, N1
Holland-Letz, T1
Babich, J1
Kratochwil, C1
Kida, Y1
Mugyenyi, P3
Walker, AS2
Hakim, J3
Munderi, P2
Gibb, DM2
Kityo, C2
Reid, A2
Grosskurth, H3
Darbyshire, JH3
Ssali, F2
Bray, D2
Katabira, E3
Babiker, AG1
Gilks, CF1
Kabuye, G1
Nsibambi, D2
Kasirye, R1
Zalwango, E1
Nakazibwe, M1
Kikaire, B1
Nassuna, G1
Massa, R1
Fadhiru, K2
Namyalo, M1
Zalwango, A1
Generous, L1
Khauka, P2
Rutikarayo, N1
Nakahima, W1
Mugisha, A1
Todd, J1
Levin, J1
Muyingo, S1
Ruberantwari, A1
Kaleebu, P2
Yirrell, D2
Ndembi, N2
Lyagoba, F2
Hughes, P1
Aber, M1
Lara, AM2
Foster, S2
Amurwon, J2
Wakholi, BN2
Whitworth, J1
Wangati, K1
Amuron, B1
Kajungu, D1
Nakiyingi, J1
Omony, W1
Tumukunde, D1
Otim, T1
Kabanda, J1
Musana, H1
Akao, J1
Kyomugisha, H1
Byamukama, A1
Sabiiti, J1
Komugyena, J1
Wavamunno, P1
Mukiibi, S1
Drasiku, A1
Byaruhanga, R1
Labeja, O1
Katundu, P2
Tugume, S2
Awio, P1
Namazzi, A1
Bakeinyaga, GT1
Katabira, H1
Abaine, D1
Tukamushaba, J1
Anywar, W1
Ojiambo, W1
Angweng, E1
Murungi, S2
Haguma, W1
Atwiine, S1
Kigozi, J3
Namale, L1
Mukose, A1
Mulindwa, G1
Atwiine, D1
Muhwezi, A1
Nimwesiga, E1
Barungi, G1
Takubwa, J1
Mwebesa, D1
Kagina, G1
Mulindwa, M1
Ahimbisibwe, F1
Mwesigwa, P1
Akuma, S1
Zawedde, C1
Nyiraguhirwa, D1
Tumusiime, C1
Bagaya, L1
Namara, W1
Karungi, J1
Kankunda, R1
Enzama, R1
Latif, A2
Robertson, V2
Chidziva, E1
Bulaya-Tembo, R1
Musoro, G1
Taziwa, F1
Chimbetete, C1
Chakonza, L1
Mawora, A1
Muvirimi, C1
Tinago, G1
Svovanapasis, P1
Simango, M1
Chirema, O1
Machingura, J1
Mutsai, S1
Phiri, M1
Bafana, T1
Chirara, M2
Muchabaiwa, L2
Muzambi, M2
Mutowo, J1
Chivhunga, T1
Chigwedere, E1
Pascoe, M1
Warambwa, C1
Zengeza, E1
Mapinge, F1
Makota, S1
Jamu, A1
Ngorima, N1
Chirairo, H1
Chitsungo, S1
Chimanzi, J1
Maweni, C1
Warara, R1
Matongo, M1
Mudzingwa, S1
Jangano, M1
Moyo, K1
Vere, L1
Mdege, N1
Machingura, I1
Ronald, A1
Kambungu, A1
Lutwama, F1
Mambule, I1
Nanfuka, A1
Walusimbi, J1
Nabankema, E1
Nalumenya, R1
Namuli, T1
Kulume, R1
Namata, I1
Nyachwo, L1
Florence, A1
Kusiima, A1
Lubwama, E1
Nairuba, R1
Oketta, F1
Buluma, E1
Waita, R1
Ojiambo, H1
Sadik, F1
Wanyama, J1
Nabongo, P1
Oyugi, J1
Sematala, F1
Muganzi, A1
Twijukye, C1
Byakwaga, H1
Ochai, R1
Muhweezi, D1
Coutinho, A1
Etukoit, B1
Gilks, C2
Boocock, K1
Puddephatt, C1
Grundy, C1
Bohannon, J1
Winogron, D1
Burke, A1
Babiker, A2
Wilkes, H1
Rauchenberger, M1
Sheehan, S1
Spencer-Drake, C1
Taylor, K1
Spyer, M1
Ferrier, A1
Naidoo, B1
Dunn, D2
Goodall, R2
Peto, L1
Nanfuka, R1
Mufuka-Kapuya, C1
Pillay, D1
McCormick, A1
Weller, I1
Bahendeka, S1
Bassett, M1
Wapakhabulo, AC1
Gazzard, B1
Mapuchere, C1
Mugurungi, O1
Burke, C1
Jones, S1
Newland, C1
Pearce, G1
Rahim, S1
Rooney, J1
Smith, M1
Snowden, W1
Steens, JM1
Breckenridge, A1
McLaren, A1
Hill, C1
Matenga, J1
Pozniak, A1
Serwadda, D1
Peto, T1
Palfreeman, A1
Borok, M1
Chang, CL1
Sullivan, GD1
Karalus, NC1
Mills, GD1
McLachlan, JD1
Hancox, RJ1
Tavafi, M1
Ahmadvand, H1
Tamjidipoor, A1
Delfan, B1
Khalatbari, AR1
Wiedmeyer, CE1
Royal, AB1
Bagshaw, SM1
Haase, M1
Haase-Fielitz, A1
Bennett, M1
Devarajan, P1
Bellomo, R1
Arkenau, HT1
Plummer, R1
Molife, LR1
Olmos, D1
Yap, TA1
Squires, M1
Lewis, S1
Calvert, H1
Judson, I1
Cleland, JG1
Carubelli, V1
Castiello, T1
Yassin, A1
Pellicori, P1
Antony, R1
Paterno, JC1
Bergamaschi, CT1
Campos, RR1
Higa, EM1
Soares, MF1
Schor, N1
Freire, AO1
Teixeira, VP1
Heras, M1
Fernández-Reyes, MJ1
Guerrero, MT1
Molina, A1
Rodríguez, MA1
Alvarez-Ude, F1
Jones, M1
Guglielmino, K1
Jackson, K1
Harris, TR1
Vu, V1
Dong, H1
Dutrow, G1
Evans, JE1
Graham, J1
Cummings, BP1
Havel, PJ1
Chiamvimonvat, N1
Despa, S1
Despa, F1
Grisk, O1
Rose, HJ1
Lorenz, G1
Rettig, R1
Salako, BL1
Finomo, FO1
Kadiri, S1
Arije, A1
Olatosin, AO1
Pita-Fernández, S1
Lorenzo-Aguiar, D1
Pértega-Díaz, S1
Valdés-Cañedo, F1
Massy, ZA1
Ivanovski, O1
Nguyen-Khoa, T1
Angulo, J1
Szumilak, D1
Mothu, N1
Phan, O1
Daudon, M1
Lacour, B1
Drüeke, TB1
Muntzel, MS1
Nosková-Lyerová, L1
Viklický, O1
Schück, O1
Zuo, L1
Ma, YC1
Zhou, YH1
Wang, M1
Xu, GB1
Wang, HY1
Schwarting, A1
Paul, K1
Tschirner, S1
Menke, J1
Hansen, T1
Brenner, W1
Kelley, VR1
Relle, M1
Galle, PR1
Bammens, B1
Evenepoel, P1
Keuleers, H1
Verbeke, K1
Vanrenterghem, Y1
Fukuda, M1
Motokawa, M1
Miyagi, S1
Sengo, K1
Muramatsu, W1
Kato, N1
Usami, T1
Yoshida, A1
Kimura, G1
Norris, KC1
Greene, T1
Kopple, J1
Lea, J1
Lewis, J1
Lipkowitz, M1
Miller, P1
Richardson, A1
Rostand, S1
Appel, LJ1
Chiang, MC1
Chen, HM1
Lee, YH1
Chang, HH1
Wu, YC1
Liu, CS1
Niu, DM1
Wu, JY1
Chen, YT1
Koh, SH1
Kim, HY1
Hwang, S1
Lee, CH1
Kim, SH1
Lan, HY1
Nikolic-Paterson, DJ1
Vannice, JL1
Atkins, RC1
Gretz, N1
Barsotti, G1
Cupisti, A1
Moriconi, L1
Cozza, V1
Falbo, E1
Gattai, V1
Pozzolini, L1
Meola, M1
West, HJ1
Ledermann, S1
Shaw, V1
Trompeter, R1
Sommer, M1
Schaller, R1
Fünfstück, R1
Bohle, A1
Böhmer, FD1
Müller, GA1
Stein, G1
Daniele, SM1
Arriaga, S1
Martínez, SM1
Tarrés, MC1
Montenegro, SM1
D'Ottavio, AE1
Hisano, N1
Picena, JC1
Morisoli, L1
Morra, DR1
Nadkarni, VM1
Bartoshesky, LE1
Finkelstein, MS1
Sasikala, M1
Sadasivudu, B1
Subramanyam, C1
Younes, H1
Alphonse, JC1
Hadj-Abdelkader, M1
Rémésy, C1
Karasek, M1
Szuflet, A1
Chrzanowski, W1
Zylinska, K1
Swietoslawski, J1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Incremental Hemodialysis as a Starting Way of Renal Replacement Therapy[NCT03302546]7 participants (Anticipated)Interventional2017-04-04Recruiting
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies[NCT00522990]Phase 1/Phase 248 participants (Actual)Interventional2006-09-30Terminated (stopped due to Recommended Phase II dose determined)
The Effects of Dietary Fiber on Uremic Retention Solutes in CKD: A Systematic Review and Meta-analysis[NCT01844882]1 participants (Actual)Observational2012-01-31Completed
A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen [NCT03939689]Phase 2120 participants (Anticipated)Interventional2019-05-30Active, not recruiting
Non-Invasive Doppler Ultrasound For Assessing Patients With Chronic Obstructive Pulmonary Disease: A Prospective Observational Study[NCT02329522]200 participants (Anticipated)Observational2014-02-28Active, not recruiting
Glycemic Control Assessed by Continuous Glucose Monitoring in Hemodialyzed Patients With Diabetes Mellitus Treated Via the Basal-Bolus Detemir-Aspart Insulin Regimen: A Pilot Study[NCT01828970]Phase 438 participants (Actual)Interventional2010-01-31Completed
Study on the Effect of Flucloxacillin on the Serum Level of P-cresol in Peritoneal Dialysis Patients[NCT00433342]Phase 19 participants (Actual)Interventional2006-03-31Terminated
A Multicentric Observational Trial on Protein Bound Uremic Toxins in Nocturnal Hemodialysis[NCT00417339]38 participants (Actual)Observational2006-12-31Completed
A Multicentric Observational Study on the Removal of Protein-Bound Uremic Retention Solutes in Nocturnal Hemodialysis: A Cross-Sectional Analysis[NCT00417105]120 participants (Actual)Observational2006-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for urea and Disease Exacerbation

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Urea and impairment of the Gut-Kidney axis in Chronic Kidney Disease.
    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2017, Dec-05, Volume: 34, Issue:Nov-Dec

    Topics: Aging; Animals; Diet, Mediterranean; Dietary Carbohydrates; Dietary Proteins; Disease Progression; D

2017
Effects of probiotic supplements on the progression of chronic kidney disease: A meta-analysis.
    Nephrology (Carlton, Vic.), 2019, Volume: 24, Issue:11

    Topics: C-Reactive Protein; Creatinine; Dietary Supplements; Disease Progression; Gastrointestinal Microbiom

2019
Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2014, Volume: 34, Issue:4

    Topics: Blood Pressure; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperur

2014
Dietary fiber effects in chronic kidney disease: a systematic review and meta-analysis of controlled feeding trials.
    European journal of clinical nutrition, 2015, Volume: 69, Issue:7

    Topics: Biomarkers; Combined Modality Therapy; Controlled Clinical Trials as Topic; Creatinine; Cross-Over S

2015
Recognising acute kidney injury.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:3

    Topics: Acute Kidney Injury; Disease Management; Disease Progression; Electrolytes; Humans; Kidney; Kidney F

2012

Trials

11 trials available for urea and Disease Exacerbation

ArticleYear
Associations between echocardiographic findings and prospective changes in residual renal function in patients new to peritoneal dialysis.
    Scientific reports, 2019, 12-05, Volume: 9, Issue:1

    Topics: Aged; Creatinine; Disease Progression; Echocardiography; Female; Follow-Up Studies; Glomerular Filtr

2019
Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial.
    Trials, 2020, Feb-19, Volume: 21, Issue:1

    Topics: Anemia; Body Weight; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Multicenter Studi

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
    The oncologist, 2021, Volume: 26, Issue:11

    Topics: Disease Progression; Gastrointestinal Stromal Tumors; Humans; Naphthyridines; Urea

2021
Progression of residual renal function with an increase in dialysis: haemodialysis versus peritoneal dialysis.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Volume: 33, Issue:5

    Topics: Adult; Aged; Anemia; beta 2-Microglobulin; Biomarkers; Creatinine; Disease Progression; Female; Foll

2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Disease Progression; Drug Adm

2014
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea

2010
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Aurora Kinases; Benzimidazoles; Cohort Studies; Disease Progress

2012
Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    African journal of medicine and medical sciences, 2002, Volume: 31, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood

2002
Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease.
    Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:10

    Topics: Adolescent; Adult; Aged; Black or African American; Creatinine; Disease Progression; Female; Glomeru

2006
Circadian serum melatonin profiles in patients suffering from chronic renal failure.
    Neuro endocrinology letters, 2002, Volume: 23 Suppl 1

    Topics: Adult; Blood Pressure; Circadian Rhythm; Creatinine; Disease Progression; Female; Humans; Kidney Fai

2002

Other Studies

59 other studies available for urea and Disease Exacerbation

ArticleYear
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2022, 01-25, Volume: 119, Issue:4

    Topics: Animals; Antigens, Surface; Binding Sites; Cell Cycle Proteins; Disease Models, Animal; Disease Prog

2022
Association of serum potassium with decline in residual kidney function in incident hemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022, 10-19, Volume: 37, Issue:11

    Topics: Disease Progression; Humans; Hyperkalemia; Kidney; Kidney Failure, Chronic; Potassium; Renal Dialysi

2022
Ultrafiltration Rate Effects Declines in Residual Kidney Function in Hemodialysis Patients.
    American journal of nephrology, 2019, Volume: 50, Issue:6

    Topics: Adult; Aged; Disease Progression; Female; Glomerular Filtration Rate; Hemodiafiltration; Humans; Kid

2019
Post-Ischemic Renal Fibrosis Progression Is Halted by Delayed Contralateral Nephrectomy: The Involvement of Macrophage Activation.
    International journal of molecular sciences, 2020, May-28, Volume: 21, Issue:11

    Topics: Acute Kidney Injury; Animals; Blood Urea Nitrogen; Chemokine CCL2; Disease Progression; Fibrosis; In

2020
Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:9

    Topics: Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lysine; Male; Middle Aged; Posi

2020
Ornithine-A urea cycle metabolite enhances autophagy and controls Mycobacterium tuberculosis infection.
    Nature communications, 2020, 07-15, Volume: 11, Issue:1

    Topics: Ammonia; Animals; Apoptosis; Arginase; Atropine; Autophagy; Cell Proliferation; Disease Progression;

2020
Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study.
    PloS one, 2020, Volume: 15, Issue:11

    Topics: Aged; Anuria; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; K

2020
Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
    Clinical journal of the American Society of Nephrology : CJASN, 2021, 02-08, Volume: 16, Issue:2

    Topics: Adult; Biomarkers; Disease Progression; Fasting; Female; Glomerular Filtration Rate; Humans; Kidney;

2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 155

    Topics: Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Male; Naphthyridines; Progress

2021
ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2017, Volume: 37, Issue:7

    Topics: ADAMTS13 Protein; Albuminuria; Animals; Cell Proliferation; Creatinine; Diabetes Mellitus, Experimen

2017
Global and targeted serum metabolic profiling of colorectal cancer progression.
    Cancer, 2017, Oct-15, Volume: 123, Issue:20

    Topics: Adenoma; Adult; Aged; Caffeine; Case-Control Studies; Chromatography, Liquid; Colonic Polyps; Colore

2017
Influence of C-reactive protein on the occurrence and assessing of albuminuria severity in diabetics.
    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 2018, Feb-01, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Blood Glucose; C-Reactive Protein; Creatini

2018
Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis.
    Medical hypotheses, 2018, Volume: 113

    Topics: Ammonia; Animals; Biopsy; Disease Models, Animal; Disease Progression; Fibrosis; Hepatic Stellate Ce

2018
High rates of protein intake are associated with an accelerated rate of decline of residual kidney function in incident peritoneal dialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 08-01, Volume: 34, Issue:8

    Topics: Adult; Aged; Diet; Dietary Proteins; Disease Progression; Female; Glomerular Filtration Rate; Humans

2019
Cyst expansion and regression in a mouse model of polycystic kidney disease.
    Kidney international, 2013, Volume: 83, Issue:6

    Topics: Age Factors; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Extracellular Matrix;

2013
Systemic perturbations of key metabolites in diabetic rats during the evolution of diabetes studied by urine metabonomics.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; Discriminant

2013
Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
    Clinical science (London, England : 1979), 2013, Volume: 125, Issue:7

    Topics: Actins; Albuminuria; Animals; Benzoates; Blood Pressure; Creatinine; Diabetes Mellitus, Experimental

2013
Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie.
    Life sciences, 2013, Jun-21, Volume: 92, Issue:23

    Topics: Animals; Benzoates; Blotting, Western; Brain; Disease Models, Animal; Disease Progression; Epoxide H

2013
Type of uromodulin mutation and allelic status influence onset and severity of uromodulin-associated kidney disease in mice.
    Human molecular genetics, 2013, Oct-15, Volume: 22, Issue:20

    Topics: Age of Onset; Alleles; Animals; Body Weight; Cystatins; Disease Models, Animal; Disease Progression;

2013
Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adult; Blood Cells; Blood Platelets; CD55 Antigens; CD59 Antigens; Complement System Proteins; Creat

2013
[Assessment of concentrations of creatinine, uric acid and urea in non-smoking and smoking patients with chronic pancreatitis].
    Przeglad lekarski, 2013, Volume: 70, Issue:10

    Topics: Creatinine; Disease Progression; Humans; Pancreatitis, Chronic; Smoking; Urea; Uric Acid

2013
Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease.
    Renal failure, 2014, Volume: 36, Issue:4

    Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Blood P

2014
Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function.
    American journal of physiology. Gastrointestinal and liver physiology, 2014, Aug-01, Volume: 307, Issue:3

    Topics: Animals; Biomarkers; Carbamoyl-Phosphate Synthase (Ammonia); Cholesterol, Dietary; Diet, High-Fat; D

2014
Modifiable factors associated with copeptin concentration: a general population cohort.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 65, Issue:5

    Topics: Adult; Alcohol Drinking; Body Mass Index; Cross-Sectional Studies; Dietary Proteins; Disease Progres

2015
High Protein Diet and Huntington's Disease.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Adult; Citrulline; Dietary Proteins; Disease Progression; Female; Humans; Huntington Disease; Male;

2015
Diagnostic Value of Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis-Associated Acute Kidney Injury.
    The Tohoku journal of experimental medicine, 2015, Volume: 237, Issue:2

    Topics: Abdomen; Acute Lung Injury; Acute-Phase Proteins; Aged; Creatinine; Critical Care; Disease Progressi

2015
Biochemical and histopathological responses of the Swiss albino mice treated with uranyl nitrate and its recovery.
    Renal failure, 2016, Volume: 38, Issue:5

    Topics: Acute Kidney Injury; Animals; Creatinine; Disease Models, Animal; Disease Progression; Dose-Response

2016
Neutrophil gelatinase-associated lipocalin in a triphasic rat model of adenine-induced kidney injury.
    Renal failure, 2016, Volume: 38, Issue:9

    Topics: Acute Kidney Injury; Adenine; Animals; Biomarkers; Creatinine; Disease Progression; Enzyme-Linked Im

2016
Characterization of an experimental model of progressive renal disease in rats.
    Acta cirurgica brasileira, 2016, Volume: 31, Issue:11

    Topics: Albuminuria; Animals; Arterial Pressure; Creatinine; Disease Models, Animal; Disease Progression; Gl

2016
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:6

    Topics: Antigens, Surface; Disease Progression; Glutamate Carboxypeptidase II; Glutamates; Humans; Iodine Ra

2017
Estimation of protein intake using urinary urea nitrogen in patients with liver cirrhosis.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:5

    Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Cohort Studies; Dietary Proteins; Dietary S

2009
Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score.
    Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aging; Blood Pressure; Confusion; Disease Progression; Female; Hospi

2011
Satureja khozestanica essential oil ameliorates progression of diabetic nephropathy in uninephrectomized diabetic rats.
    Tissue & cell, 2011, Volume: 43, Issue:1

    Topics: Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; G

2011
Urinary biomarkers for monitoring disease progression in the Han:SPRD-cy rat model of autosomal-dominant polycystic kidney disease.
    Comparative medicine, 2010, Volume: 60, Issue:6

    Topics: Acetylglucosaminidase; Albuminuria; Animals; Biomarkers; Collagen Type IV; Creatinine; Disease Progr

2010
A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:2

    Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Cohort Studies; Creatinine; Critical Illness; Disease

2012
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis.
    Heart failure reviews, 2012, Volume: 17, Issue:2

    Topics: Biomarkers; Creatinine; Disease Progression; Heart Failure; Humans; Incidence; Kidney; Kidney Diseas

2012
Electroacupuncture and moxibustion decrease renal sympathetic nerve activity and retard progression of renal disease in rats.
    Kidney & blood pressure research, 2012, Volume: 35, Issue:5

    Topics: Animals; Blood Pressure; Creatinine; Disease Models, Animal; Disease Progression; Electroacupuncture

2012
Elderly patients with chronic kidney disease: outcomes after 5 years of follow-up.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, May-14, Volume: 32, Issue:3

    Topics: Aged; Aged, 80 and over; Chronic Disease; Comorbidity; Creatinine; Diabetic Nephropathies; Disease P

2012
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
    American journal of physiology. Heart and circulatory physiology, 2012, Oct-01, Volume: 303, Issue:7

    Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes

2012
Sympathetic-renal interaction in chronic arterial pressure control.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2002, Volume: 283, Issue:2

    Topics: Animals; Animals, Newborn; Arteriosclerosis; Blood Pressure; Body Weight; Creatinine; Crosses, Genet

2002
Progression of renal disease measured by the reciprocal of serum creatinine.
    Renal failure, 2003, Volume: 25, Issue:4

    Topics: Adult; Aged; Biomarkers; Blood Pressure; Creatinine; Diastole; Disease Progression; Female; Humans;

2003
Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:1

    Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Body Weight; Calcinosis; Cholesterol; Collagen;

2005
[Hypernatraemia, increased protein intake and progression of renal insufficiency in a patient with polycystic renal degeneration].
    Vnitrni lekarstvi, 2001, Volume: 47, Issue:3

    Topics: Cerebral Hemorrhage; Dietary Proteins; Disease Progression; Diuresis; Humans; Hypernatremia; Male; M

2001
Application of GFR-estimating equations in Chinese patients with chronic kidney disease.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3

    Topics: Adult; Aged; Algorithms; China; Creatinine; Disease Progression; Female; Glomerular Filtration Rate;

2005
Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:11

    Topics: Animals; Cell Division; Disease Models, Animal; Disease Progression; Flow Cytometry; Immunoglobulin

2005
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
    Kidney international, 2006, Volume: 69, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Confidence Intervals; Creatinine; Cresols; Disease P

2006
Polynocturia in chronic kidney disease is related to natriuresis rather than to water diuresis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:8

    Topics: Blood Pressure; Chronic Disease; Circadian Rhythm; Creatinine; Disease Progression; Diuresis; Female

2006
Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease.
    Human molecular genetics, 2007, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Brain-Derived Neurotrophic Factor; CCAAT-Enhancer-Binding Protein-alpha; Citrulline; Diet;

2007
Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS.
    Experimental neurology, 2007, Volume: 205, Issue:2

    Topics: Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Caspase 3; Cell Death; Cyclooxygenase 2;

2007
Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat.
    Kidney international, 1995, Volume: 47, Issue:5

    Topics: Analysis of Variance; Animals; Cell Division; Creatinine; Disease Progression; Glomerulonephritis; I

1995
Progression of chronic renal failure in a rat strain with autosomal dominant polycystic kidney disease.
    Nephron, 1994, Volume: 68, Issue:4

    Topics: Animals; Blood Pressure; Creatinine; Disease Progression; Kidney; Kidney Failure, Chronic; Longitudi

1994
Effects of reduced protein intake in rats with congenital polycystic kidney without renal failure.
    Contributions to nephrology, 1995, Volume: 115

    Topics: Animals; Body Weight; Creatinine; Diet, Protein-Restricted; Disease Progression; Male; Polycystic Ki

1995
Clinical and pathological studies in horses with hepatic disease.
    Equine veterinary journal, 1996, Volume: 28, Issue:2

    Topics: Ammonia; Animals; Bile Acids and Salts; Bilirubin; Biopsy; Blood Glucose; Disease Progression; Femal

1996
Low-protein diet and progression of chronic renal failure.
    Lancet (London, England), 1997, Jul-12, Volume: 350, Issue:9071

    Topics: Child; Diet, Protein-Restricted; Dietary Proteins; Disease Progression; Glomerular Filtration Rate;

1997
Abnormal growth and clonal proliferation of fibroblasts in an animal model of unilateral ureteral obstruction.
    Nephron, 1999, Volume: 82, Issue:1

    Topics: Animals; Cell Division; Cells, Cultured; Collagen; Collagenases; Creatinine; Disease Models, Animal;

1999
Onset and evolution of nephropathy in rats with spontaneous diabetes mellitus.
    Journal of physiology and biochemistry, 2000, Volume: 56, Issue:1

    Topics: Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies;

2000
RC--a case of ornithine transcarbamylase (OTC) deficiency. The most commonly genetically acquired urea cycle defect.
    Delaware medical journal, 2000, Volume: 72, Issue:8

    Topics: Blood Chemical Analysis; Child, Preschool; Disease Progression; Fatal Outcome; Female; Humans; Liver

2000
A putative role for calcineurin in lymphopenia associated with chronic renal failure.
    Clinical biochemistry, 2000, Volume: 33, Issue:8

    Topics: Adult; Animals; Calcineurin; Cattle; Creatinine; Disease Progression; Female; Humans; Kidney Failure

2000
Fermentable carbohydrate and digestive nitrogen excretion.
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2001, Volume: 11, Issue:3

    Topics: Ammonia; Animals; Cecum; Dietary Carbohydrates; Dietary Proteins; Disease Models, Animal; Disease Pr

2001